BioSpace News Archive

Teva to Present Data for AUSTEDO ® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO ® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023.

Forma Medical , an emerging innovator in medical device technologies, announces today the launch of OptimalHT, the world’s first instrumented Minimally Invasive Surgery (MIS) Hammertoe Arthrodesis procedure, that has treated more than 50 hammertoe deformities.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a virtual analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference.

Inozyme Pharma, Inc. today announced that it granted stock options to a new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan.

Femasys Inc. today announced that Kathy Lee-Sepsick, founder, president & chief executive officer, will virtually present and also participate in one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.

NeuroSense Therapeutics Ltd. announced it will host an investor webinar conference on Tuesday, September 12, 2023 from 8:30 AM to 9:15 AM Eastern Time.

ThermoGenesis Holdings, Inc. today announced that Chris Xu , Ph.D., Chief Executive Officer, will present a company overview on Wednesday, September 13, at 4:30 pm ET.

AcelRx Pharmaceuticals, Inc. today announced that Chief Executive Officer, Vince Angotti will present in-person and be available for one-on-one meetings throughout the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY.

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it has entered into a licensing agreement with Giiant Pharma, Inc. (“Giiant”).

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m. ET on Tuesday, September 12, 2023.